Literature DB >> 24939620

Dimorphic fungal osteoarticular infections.

B Rammaert1, M N Gamaletsou, V Zeller, C Elie, R Prinapori, S J Taj-Aldeen, E Roilides, D P Kontoyiannis, B Brause, N V Sipsas, T J Walsh, O Lortholary.   

Abstract

The objective of this investigation was to review the clinical manifestations, management, and outcome of osteoarticular infections caused by dimorphic fungi. We exhaustively reviewed reports of bone and joint infections caused by dimorphic fungi published between 1970 and 2012. Underlying conditions, microbiological features, histological characteristics, clinical manifestations, antifungal therapy, and outcome were analyzed in 222 evaluable cases. Among 222 proven cases (median age 41 years [interquartile range (IQR) 26-57]), 73 % had no predisposing condition. Histopathology performed in 128 (57 %) cases and culture in 170 confirmed diagnosis in 63 % and 98 % of the cases, respectively. Diagnosis was obtained from an extra-osteoarticular site in 16 cases. The median diagnostic time was 175 days (IQR 60-365). Sporothrix schenckii was the most frequent pathogen (n = 84), followed by Coccidioides immitis (n = 47), Blastomyces dermatitidis (n = 44), Histoplasma capsulatum (n = 18), Paracoccidioides brasiliensis (n = 16), and Penicillium marneffei (n = 13). Arthritis occurred in 87 (58 %) cases and osteomyelitis in 64 (42 %), including 19 vertebral osteomyelitis. Dissemination was reported in 123 (55 %) cases. Systemic antifungal agents were used in 216 (97 %) patients and in combination with surgery in 129 (60 %). Following the Infectious Diseases Society of America (IDSA) guidelines, a successful initial medical strategy was observed in 97/116 (84 %) evaluable cases. The overall mortality was 6 %, and was highest for P. marneffei (38.5 %). This study demonstrates that dimorphic osteoarticular infections have distinctive clinical presentations, occur predominantly in apparently immunocompetent patients, develop often during disseminated disease, and may require surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24939620     DOI: 10.1007/s10096-014-2149-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  39 in total

1.  In vitro evaluation of voriconazole against some clinically important fungi.

Authors:  M R McGinnis; L Pasarell; D A Sutton; A W Fothergill; C R Cooper; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Sporotrichosis in Peru: description of an area of hyperendemicity.

Authors:  P G Pappas; I Tellez; A E Deep; D Nolasco; W Holgado; B Bustamante
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

3.  Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam.

Authors:  Thuy Le; Marcel Wolbers; Nguyen Huu Chi; Vo Minh Quang; Nguyen Tran Chinh; Nguyen Phu Huong Lan; Pham Si Lam; Michael J Kozal; Cecilia M Shikuma; Jeremy N Day; Jeremy Farrar
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

Review 4.  Blastomycosis: organ involvement and etiologic diagnosis. A review of 123 patients from Mississippi.

Authors:  L B Lemos; M Guo; M Baliga
Journal:  Ann Diagn Pathol       Date:  2000-12       Impact factor: 2.090

Review 5.  New perspectives on coccidioidomycosis.

Authors:  Neil M Ampel
Journal:  Proc Am Thorac Soc       Date:  2010-05

6.  An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.

Authors:  Flavio Queiroz-Telles; Luciano Z Goldani; Haran T Schlamm; James M Goodrich; Ana Espinel-Ingroff; Maria A Shikanai-Yasuda
Journal:  Clin Infect Dis       Date:  2007-10-22       Impact factor: 9.079

7.  Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery.

Authors:  Caspar J Hodiamont; Koert M Dolman; Ineke J M Ten Berge; Willem J G Melchers; Paul E Verweij; Dasja Pajkrt
Journal:  Med Mycol       Date:  2008-12-19       Impact factor: 4.076

8.  In vitro antifungal drug susceptibilities of Penicillium marneffei from China.

Authors:  Donghua Liu; Ling Liang; Jimin Chen
Journal:  J Infect Chemother       Date:  2012-10-28       Impact factor: 2.211

Review 9.  Coccidioidomycosis in persons infected with HIV-1.

Authors:  Neil M Ampel
Journal:  Ann N Y Acad Sci       Date:  2007-03-15       Impact factor: 5.691

10.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

View more
  9 in total

Review 1.  Spinal blastomycosis: unusual musculoskeletal presentation with literature review.

Authors:  Seyed Emamian; Michael G Fox; Dustin Boatman; Felicia D Allard; Nicholas C Nacey
Journal:  Skeletal Radiol       Date:  2019-05-28       Impact factor: 2.199

2.  Coccidioides immitis septic knee arthritis.

Authors:  Scott A Weisenberg
Journal:  BMJ Case Rep       Date:  2018-03-13

Review 3.  Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century.

Authors:  Saad J Taj-Aldeen; Maria N Gamaletsou; Blandine Rammaert; Nikolaos V Sipsas; Valerie Zeller; Emmanuel Roilides; Dimitrios P Kontoyiannis; Michael Henry; Vidmantas Petraitis; Brad Moriyama; David W Denning; Olivier Lortholary; Thomas J Walsh
Journal:  Med Mycol       Date:  2017-10-01       Impact factor: 4.076

4.  Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases.

Authors:  Maria N Gamaletsou; Blandine Rammaert; Marimelle A Bueno; Nikolaos V Sipsas; Brad Moriyama; Dimitrios P Kontoyiannis; Emmanuel Roilides; Valerie Zeller; Saad J Taj-Aldeen; Michael Henry; Vidmantas Petraitis; David W Denning; Olivier Lortholary; Thomas J Walsh
Journal:  Med Mycol       Date:  2017-04-01       Impact factor: 4.076

5.  Prosthetic Joint Infections Due to Histoplasma capsulatum: A Report of 3 Cases.

Authors:  Hadi E Berbari; Pooja Gurram; Maryam Mahmood; Paul J Deziel; Randall C Walker; Raymund R Razonable
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-01-21

6.  Disseminated Coccidioidomycosis Presenting as Polyarticular Septic Arthritis: A Case Report.

Authors:  Faisal Nasrawi; Arash Heidari; Thulfiqar Aljashamy; Nishan Mangat; Jasbir Bhaika; Simmer Kaur; Rasha Kuran; Royce Johnson
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

Review 7.  Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients: A Systematic Review.

Authors:  Saad J Taj-Aldeen; Blandine Rammaert; Maria Gamaletsou; Nikolaos V Sipsas; Valerie Zeller; Emmanuel Roilides; Dimitrios P Kontoyiannis; Andy O Miller; Vidmantas Petraitis; Thomas J Walsh; Olivier Lortholary
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

8.  Chronic fungal osteomyelitis of the tibia due to Acremonium curvulum: a rare case.

Authors:  Sadia Khan; Anil Kumar; Vadakekoottu Bhaskaran; Sabthami Chandran; Kavitha Dinesh
Journal:  Pan Afr Med J       Date:  2019-12-03

9.  Resorbable Beads Provide Extended Release of Antifungal Medication: In Vitro and In Vivo Analyses.

Authors:  Yung-Heng Hsu; Huang-Yu Chen; Jin-Chung Chen; Yi-Hsun Yu; Ying-Chao Chou; Steve Wen-Neng Ueng; Shih-Jung Liu
Journal:  Pharmaceutics       Date:  2019-10-24       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.